Group items tagged

Michael Mullan, CEO and President of the Roskamp Institute and researcher of Alzheimer Disease Sarasota, FL - 34243.

Check reviews and rating of Michael Mullan Sarasota, FL - 3443 and also get phone numbers, and addresses for Michael Mullan.

Michael Mullan - Roskamp Institute - Sarasota, FL - Royal Free School of Medicine. He research to cure Alzheimer's Disease.

View Michael Mullan's professional profile on LinkedIn. Dr Michael Mullan, CEO and President of the Roskamp Institute, Sarasota, FL. He research to cure Alzheimer's Disease. He discovered Swedish Mutation in the Amyloid Precursor Protein gene that is widely used in Alzheimer's research today.

Dr Mullan is CEO and President of the Roskamp Institute, Sarasota, FL. He do research to cure Alzheimer's Disease. The authoritative source of Michael Mullan personal information, links, and social activity.

Dr michael mullan CEO of roskamp institute, sarasota, FL. Michael mullan is a holder of Licentiate in Medicine and Surgery of the Society of Apothecaries, UK.

Join Nature Network to connect to Michael Mullan sarasota, FL. Connect with the professional networking website for scientists around the world.

Michael Mullan, CEO and President of the Roskamp Institute, Sarasota, FL. He is a biomedical researcher of the beta amyloid protein and its relation to Alzheime.

Michael Mullan, CEO and President of the Roskamp Institute, Sarasota, FL. He is a leading expert in alzheimers research and other neurodegnerative disorder.

Michael Mullan, CEO and President of the Roskamp Institute, Sarasota, FL. He research to cure Alzheimer's Disease. He discovered Swedish Mutation in the Amyloid Precursor Protein gene that is widely used in Alzheimer's research today. Michael Mullan is a leading expert in Alzheimers Research and other neurodegnerative disorder.

"November 25, 2009 | Michael O'Riordan Orlando, FL - Treating healthy women with low LDL cholesterol but elevated high-sensitivity C-reactive protein (hsCRP) levels with rosuvastatin (Crestor, AstraZeneca) cuts their risk of cardiovascular events in half, according to a new analysis of Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The reduction in risk is consistent with the reduction observed in the overall trial, and with the 42% benefit observed in men.

Bushinsky DA, Krieger NS, Geisser DI, Grossman EB, Coe FL. Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol. 1983 Aug;245(2):F204-9. PMID: 6881337 [PubMed - indexed for MEDLINE]

[Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density] Souza HN, Lora FL, Kulak CA, Mañas NC, Amarante HM, Borba VZ. Arq Bras Endocrinol Metabol. 2008 Jun;52(4):684-91. Portuguese. PMID: 18604382

Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC). Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Am J Epidemiol. 2009 Apr 9. [Epub ahead of print] PMID: 19359375 doi:10.1093/aje/kwp022

"March 29, 2009 | Michael O'Riordan Orlando, FL - Reducing LDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) in primary-prevention patients treated with rosuvastatin (Crestor, AstraZeneca) results in better event-free survival than when neither of these targets are achieved or when LDL cholesterol alone is reduced, a new analysis shows [1]. Presenting the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study during an afternoon press conference at the American College of Cardiology 2009 Scientific Sessions, investigators say that initial interventions for low-risk primary-prevention patients remains lifestyle and dietary modifications, but for those choosing drug therapy, "reductions in both LDL cholesterol and hs-CRP are indicators of the success of treatment with statin therapy.""

"November 24, 2009 | Lisa Nainggolan Orlando, FL - Inadequate levels of vitamin D are associated with an increase in the risk of cardiovascular disease and death, a new observational study has found. Dr Tami L Bair (Intermountain Medical Center, Murray, UT) reported the findings here at the American Heart Association 2009 Scientific Sessions. Bair and colleagues followed more than 27 000 people 50 years or older with no history of cardiovascular disease for just over a year and found that those with very low levels of vitamin D (30 ng/mL). Those deficient in vitamin D were also twice as likely to develop heart failure as those with normal levels. "We concluded that even a moderate deficiency of vitamin D was associated with developing coronary artery disease, heart failure, stroke, and death," said coauthor Dr Heidi May (Intermountain Medical Center). However, "it is not known whether this is a cause and effect relationship," she told heartwire. Because this study was observational, more research is needed "to better establish the association between vitamin D deficiency and cardiovascular disease," she noted."

Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Am J Epidemiol. 2009 May 15;169(10):1223-32. Epub 2009 Apr 9. PMID: 19359375 In summary, the results of this large nested case-control study provide no evidence in support of a protective effect of circulating concentrations of vitamin D on the risk of prostate cancer.

"Orlando, FL - Adding extended-release niacin (Niaspan, Abbott) to statin therapy results in a significant regression of atherosclerosis as measured by carotid intima-media thickness (IMT), whereas the addition of ezetimibe (Zetia, Merck/Schering-Plough) to statin therapy did not, according to an eagerly anticipated study "

Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. J Hum Hypertens. 2007 Apr;21(4):297-306. Epub 2007 Feb 8. PMID: 17287847 We conclude that coenzyme Q10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects.

"March 18, 2009 | Marlene Busko Palm Harbor, FL - In a large study of adolescents, low serum levels of 25-dihydroxyvitamin D (25[OH]D) strongly predicted prevalence of hypertension, hyperglycemia, and metabolic syndrome [1]. The findings were reported at the AHA 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention. Adolescents with vitamin-D levels in the lowest quartile were almost four times more likely to have metabolic syndrome than those with vitamin-D levels in the highest quartile. "I think that is quite alarming," lead author Dr Jared P Reis (Johns Hopkins Medical Institutions, Baltimore, MD) said in an AHA podcast issued to the media."